Trevena, Inc. (TRVN): Price and Financial Metrics


Trevena, Inc. (TRVN): $0.16

0.00 (0.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TRVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TRVN Stock Summary

  • TREVENA INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.51% of US listed stocks.
  • With a price/sales ratio of 133.73, TREVENA INC has a higher such ratio than 98.14% of stocks in our set.
  • As for revenue growth, note that TRVN's revenue has grown -94.21% over the past 12 months; that beats the revenue growth of only 1.09% of US companies in our set.
  • Stocks that are quantitatively similar to TRVN, based on their financial statements, market capitalization, and price volatility, are RNLX, APPN, YQ, MASS, and ITCI.
  • TRVN's SEC filings can be seen here. And to visit TREVENA INC's official web site, go to www.trevena.com.

TRVN Valuation Summary

  • In comparison to the median Healthcare stock, TRVN's price/sales ratio is 7452.63% higher, now standing at 143.5.
  • TRVN's price/earnings ratio has moved up 8.6 over the prior 105 months.

Below are key valuation metrics over time for TRVN.

Stock Date P/S P/B P/E EV/EBIT
TRVN 2022-09-23 143.5 0.8 -0.5 -0.2
TRVN 2022-09-22 152.0 0.8 -0.5 -0.2
TRVN 2022-09-21 155.5 0.9 -0.5 -0.3
TRVN 2022-09-20 158.0 0.9 -0.5 -0.3
TRVN 2022-09-19 160.5 0.9 -0.5 -0.3
TRVN 2022-09-16 165.0 0.9 -0.6 -0.3

TRVN Growth Metrics

    Its 4 year revenue growth rate is now at -99.45%.
  • The 3 year net income to common stockholders growth rate now stands at -115.86%.
  • Its 5 year net cashflow from operations growth rate is now at 70.68%.
TRVN's revenue has moved down $32,000 over the prior 33 months.

The table below shows TRVN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 0.2 -54.736 -59.094
2022-03-31 0.378 -54.457 -58.135
2021-12-31 0.567 -50.197 -51.588
2021-09-30 0.637 -44.713 -49.506
2021-06-30 3.456 -35.523 -41.286
2021-03-31 3.278 -29.173 -33.486

TRVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TRVN has a Quality Grade of C, ranking ahead of 33.81% of graded US stocks.
  • TRVN's asset turnover comes in at 0.029 -- ranking 357th of 680 Pharmaceutical Products stocks.
  • SIGA, FBRX, and INFI are the stocks whose asset turnover ratios are most correlated with TRVN.

The table below shows TRVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.029 0.826 -3.505
2021-03-31 0.030 0.895 -2.700
2020-12-31 0.035 0.941 -2.283
2020-09-30 0.044 1.000 -1.557
2020-06-30 0.001 1.000 -1.390
2020-03-31 0.001 1.000 -0.927

TRVN Price Target

For more insight on analysts targets of TRVN, see our TRVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.25 Average Broker Recommendation 1.62 (Moderate Buy)

TRVN Stock Price Chart Interactive Chart >

Price chart for TRVN

TRVN Price/Volume Stats

Current price $0.16 52-week high $1.24
Prev. close $0.16 52-week low $0.15
Day low $0.16 Volume 220,423
Day high $0.16 Avg. volume 1,313,347
50-day MA $0.21 Dividend yield N/A
200-day MA $0.38 Market Cap 27.46M

Trevena, Inc. (TRVN) Company Bio


Trevena Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and intent to commercialize therapeutics for G protein coupled receptors. The company was founded in 2007 and is based in King of Prussia, Pennsylvania.


TRVN Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVN Latest Social Stream


Loading social stream, please wait...

View Full TRVN Social Stream

Latest TRVN News From Around the Web

Below are the latest news stories about TREVENA INC that investors may wish to consider to help them evaluate TRVN as an investment opportunity.

Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference

CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York. Presentation DetailsDate: Monday, September 12, 2022Time: 4:30pm ETWeb

Yahoo | September 7, 2022

What Makes Trevena (TRVN) a New Buy Stock

Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | August 16, 2022

Analysts Offer Insights on Healthcare Companies: Trevena (TRVN) and Nkarta (NKTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevena (TRVN – Research Report) and Nkarta (NKTX – Research Report) with bullish sentiments. Trevena (TRVN) H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Trevena today and set a price target of $1.50. The company's shares closed last Thursday at $0.24, close to its 52-week low of $0.18. According to TipRanks.

Catie Powers on TipRanks | August 12, 2022

We're A Little Worried About Trevena's (NASDAQ:TRVN) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | August 12, 2022

Analysts Are Bullish on Top Healthcare Stocks: Trevena (TRVN), Zealand Pharma (ZEAL)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Trevena (TRVN – Research Report) and Zealand Pharma (ZEAL – Research Report) with bullish sentiments. Trevena (TRVN) JMP Securities analyst Jason Butler reiterated a Buy rating on Trevena today and set a price target of $2.00. The company's shares closed last Thursday at $0.24, close to its 52-week low of $0.18. According to TipRanks.

Catie Powers on TipRanks | August 11, 2022

Read More 'TRVN' Stories Here

TRVN Price Returns

1-mo -22.29%
3-mo -56.76%
6-mo -63.16%
1-year -87.10%
3-year -83.77%
5-year -93.70%
YTD -72.53%
2021 -72.78%
2020 154.49%
2019 95.56%
2018 -73.13%
2017 -72.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6657 seconds.